No More than the Relief Needed

RELIEF With Less Acetaminophen
  • Contains the lowest FDA-approved dose of acetaminophen (300 mg) in a butalbital combination prescription product1-8
RELIEF With No Caffeine1
  • Caffeine-containing medications have been associated with nervousness, dizziness9
RELIEF With No Aspirin1
RELIEF With Proven Active Ingredients1

EACH TABLET CONTAINS:

Butalbital, USP 50 mg

Warning: may be habit-forming

Acetaminophen, USP 300 mg

Relief Without Adding to the Daily Caffeine Load

400 mg of Caffeine/Day Is Believed to Be a Safe Allowance10
Caffeine Prevalence in the United States
  • All adults ≥22 years of age: Average caffeine intake is approximately 300 mg/day11
  • Regular coffee drinkers: Average caffeine intake from coffee alone is approximately 375 mg/day
    (~3 cups of coffee/day)11,12
    • - Coffee is the most commonly consumed beverage after water12
    • - 61% of population aged 18 and older are coffee drinkers12
    • - Almost 2/3 of the US population intakes ~94% of its daily caffeine allowance from coffee alone10-12
HEAVY DAILY CAFFEINE INTAKE (>500 TO
600 MG A DAY) MAY be associated with13
Insomnia Restlessness/ Nervousness Fast Heartbeat
Irritability Stomach Upset Muscle Tremors
Risk vs. Benefit
Data from 2012 Cochrane Review Suggest
  • Medications containing caffeine have an analgesic effect at doses of ≥100 mg but not ≤65 mg 14
  • Efficacy at doses between these boundaries is unclear14

Demand Brand-Name BUPAP for Co-pay Savings

For Doctors For Patients
  • Indicate no substitution to avoid a switch at the pharmacy
  • Check your prescription to make sure it’s written for brand-name BUPAP
  • Indicate "DAW," "Brand Only," or
    "Brand Medically Necessary" depending on the
    state you live in
  • Check your bag at the pharmacy to make sure you didn’t receive a generic alternative
  • The Co-pay Card only works when the brand-name drug is dispensed
  • Check your receipt for your prescription savings if you are using the Co-pay Card

*Offer restrictions and eligibility requirements: Offer is not valid for prescriptions being fully or partially reimbursed under Medicaid, a Medicare drug benefit plan, or other federal or state programs (such as medical assistance programs). The patient is responsible for reporting receipt of this offer to any health insurer, health plan, or third-party payer as may be required. By using this card, you agree that you will not submit a claim for the prescription to a government payer. If any part of your prescription is paid for by a nongovernmental third-party payer, you attest to having disclosed this offer to your third-party payer. The use of this card is subject to applicable state and federal law.



INDICATION

BUPAP® Tablets (butalbital and acetaminophen 50 mg/300 mg) are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product.

  • BUPAP is contraindicated under the following conditions:
    • Hypersensitivity or intolerance to any component of this product.
    • Patients with porphyria.
  • Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.
  • Acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of severe skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
  • The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
  • There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs include swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue BUPAP immediately and seek medical care if they experience these symptoms. Do not prescribe BUPAP for patients with acetaminophen allergy.
  • BUPAP should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.
  • The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.
» Click here for full Prescribing Information.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDICATION

BUPAP® Tablets (butalbital and acetaminophen 50 mg/300 mg) are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

IMPORTANT SAFETY INFORMATION

Hepatotoxicity: Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen containing product.

  • BUPAP is contraindicated under the following conditions:
    • Hypersensitivity or intolerance to any component of this product.
    • Patients with porphyria.
  • Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.
  • Acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of severe skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.
  • The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.
  • There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs include swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue BUPAP immediately and seek medical care if they experience these symptoms. Do not prescribe BUPAP for patients with acetaminophen allergy.
  • BUPAP should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.
  • The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.
» Click here for full Prescribing Information.